IL-8和MMP-2在非小细胞肺癌患者胸腔镜肺段切除术预后评估中的价值

doi:10.3969/j.issn.1673-8640.2023.04.008

摘要/Abstract

摘要：

目的探讨血清白细胞介素8（IL-8）、基质金属蛋白酶2（MMP-2）水平在非小细胞肺癌（NSCLC）患者胸腔镜肺段切除术预后评估中的价值。方法选取101例行胸腔镜肺段切除术的NSCLC患者。收集所有患者的一般资料，检测其术前血清IL-8和MMP-2水平。对所有患者随访3年，根据是否出现复发分为复发组和未复发组。采用二元Logistic回归分析评估影响NSCLC患者复发的危险因素。采用受试者工作特征（ROC）曲线评价IL-8、MMP-2判断NSCLC患者复发的效能。采用Kaplan-Meier生存曲线和Log-rank χ²检验评估NSCLC患者的复发情况。结果复发组术前血清IL-8、MMP-2水平显著高于未复发组（P<0.05）。以IL-8和MMP-2的均值分别作为临界值，将所有患者分为高表达组和低表达组。二元Logistic回归分析结果显示，术前血清IL-8≥87.52 ng/L和MMP-2≥477.86 ng/mL均是NSCLC患者复发的危险因素[比值比（OR）值分别为24.50、23.56，95%可信区间（CI）分别为18.94~37.23、18.01~38.29]。ROC曲线分析结果显示，术前IL-8和MMP-2判断NSCLC患者复发的曲线下面积（AUC）分别为0.834、0.858。Kaplan-Meier生存曲线分析结果显示，IL-8高表达组和MMP-2高表达组累积复发率分别显著高于IL-8低表达组和MMP-2低表达组（P<0.001）。结论术前血清IL-8、MMP-2水平可作为评估NSCLC患者胸腔镜肺段切除术预后的生物标志物。

关键词: 白细胞介素8, 基质金属蛋白酶2, 胸腔镜肺段切除术, 非小细胞肺癌

Abstract:

Objective To investigate the roles of serum interleukin-8（IL-8）and matrix metalloproteinase-2（MMP-2） levels in predicting the prognosis of non-small cell lung cancer（NSCLC） patients undergoing thoracoscopic segmentectomy. Methods Totally，101 patients with NSCLC who underwent thoracoscopic segmentectomy were enrolled. The general data were collected. IL-8 and MMP-2 were determined. The patients were followed up for 3 years. According to whether the patients had recurrence，they were classified into recurrence group and non-recurrence group. Binary Logistic regression analysis was used to analyze the risk factors affecting recurrence. Receiver operating characteristic（ROC） curve was used to analyze the clinical value of preoperative serum IL-8 and MMP-2 levels in predicting the prognosis of patients. Kaplan-Meier survival curve and Log-rank χ² analysis were used to analyze the recurrence rate of NSCLC patients. Results Compared with non-recurrence group，the preoperative serum IL-8 and MMP-2 levels were higher in recurrence group（P<0.05）. The levels of IL-8 and MMP-2 were taken as cut-off values，and all the patients were classified into high expression group and low expression group. The results of binary Logistic regression analysis showed that preoperative serum IL-8≥87.52 ng/L and MMP-2≥477.86 ng/mL are independent risk factors that affected recurrence[odds ratios（OR） were 24.50 and 23.56，95% confidence intervals（CI） were 18.94-37.23 and 18.01-38.29]. ROC curve results showed that the area under curve（AUC） of IL-8 predicting recurrence was 0.834，and the AUC of MMP-2 predicting recurrence was 0.858. The results of Kaplan-Meier survival curve analysis showed that compared with IL-8 low expression group or MMP-2 low expression group，IL-8 high expression group or MMP-2 high expression group had a higher cumulative recurrence rate（P<0.001）. Conclusions The preoperative serum IL-8 and MMP-2 levels can be used as biological markers to evaluate the prognosis of patients with NSCLC after thoracoscopic segmentectomy.

Key words: Interleukin-8, Matrix metalloproteinase-2, Thoracoscopic segmentectomy, Non-small cell lung cancer

中图分类号:

R446.1

杨忠信, 李晓宇, 陈涛, 曹文军. IL-8和MMP-2在非小细胞肺癌患者胸腔镜肺段切除术预后评估中的价值[J]. 检验医学, 2023, 38(4): 342-346.

YANG Zhongxin, LI Xiaoyu, CHEN Tao, CAO Wenjun. Roles of IL-8 and MMP-2 in the prognosis of non-small cell lung cancer patients after thoracoscopic segmentectomy[J]. Laboratory Medicine, 2023, 38(4): 342-346.

图/表 6

参考文献 18.

1.	JAIN A, FUJIOKA N, PATEL M. Immune checkpoint inhibitors in ROS1-rearranged non-small cell lung cancer:a report of two cases[J]. J Thorac Oncol, 2019, 14(8):e165-e167. DOI URL
2.	彭焦武, 孙承谋. miR-124a和miR-449a对非小细胞肺癌的诊断价值[J]. 检验医学, 2021, 36(1):34-38.
3.	SU H, XIE H, DAI C, et al. Procedure-specific prognostic impact of micropapillary subtype may guide resection strategy in small-sized lung adenocarcinomas:a multicenter study[J]. Ther Adv Med Oncol, 2020, 12: 1758835920937893.
4.	D'ANDRILLI A, RENDINA E A. POINT:should segmentectomy rather than lobectomy be the operation of choice for early-stage non-small cell lung cancer? Yes[J]. Chest, 2018, 153(3):590-592. DOI URL
5.	QIU B, JI Y, HE H, et al. Three-dimensional reconstruction/personalized three-dimensional printed model for thoracoscopic anatomical partial-lobectomy in stage Ⅰ lung cancer:a retrospective study[J]. Transl Lung Cancer Res, 2020, 9(4):1235-1246. DOI URL
6.	陶绍霖, 康珀铭, 李青元, 等. 三维CT支气管血管成像在机器人肺段切除术中的临床应用[J]. 中国胸心血管外科临床杂志, 2020, 27(10):1155-1160.
7.	王子谨, 张晓膺. 载脂蛋白M在非小细胞肺癌A549细胞增殖、迁移和侵袭中的作用[J]. 检验医学, 2020, 35(9):937-942.
8.	LIPPITZ B E. Cytokine patterns in patients with cancer:a systematic review[J]. Lancet Oncol, 2013, 14(6):e218-e228. DOI URL
9.	LIU G, REN F, SONG Y. Upregulation of SPOCK2 inhibits the invasion and migration of prostate cancer cells by regulating the MT1-MMP/MMP2 pathway[J]. PeerJ, 2019, 7:e7163. DOI URL
10.	JELENIEWICZ W, CYBULSKI M, NOWAKOWSKI A, et al. MMP-2 mRNA expression in ovarian cancer tissues predicts patients' response to platinum-taxane chemotherapy[J]. Anticancer Res, 2019, 39(4):1821-1827. DOI PMID
11.	TUNG B, MA D, WANG S, et al. Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells[J]. BMC Cancer, 2018, 18(1):1025. DOI PMID
12.	OTSUKA K, TAKEHARA A, CHIBA N, et al. Identification of KLF9 and BCL3 as transcription factors that enhance reprogramming of primordial germ cells[J]. PLoS One, 2018, 13(10):e0205004. DOI URL
13.	BAGATI A, MOPARTHY S, FINK E E, et al. KLF9-dependent ROS regulate melanoma progression in stage-specific manner[J]. Oncogene, 2019, 38(19):3585-3597. DOI PMID
14.	BOBOILA S, LOPEZ G, YU J, et al. Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma[J]. Oncogene, 2018, 37(40):5451-5465. DOI PMID
15.	ZUCCARI D A, LEONEL C, CASTRO R, et al. An immunohistochemical study of interleukin-8(IL-8) in breast cancer[J]. Acta Histochem, 2012, 114(6):571-576. DOI URL
16.	杨云鹏, 刘莉, 李慧. MMP-2、MMP-3和MMP-9在胃癌患者中的表达及意义[J]. 局解手术学杂志, 2016, 25(9):625-628.
17.	刘东雷, 吴恺, 吉浩哲, 等. 环氧化酶-2、基质金属蛋白酶2、基质金属蛋白酶9在非小细胞肺癌中的表达及意义[J]. 癌症进展, 2020, 18(12):1236-1239.
18.	刘霞, 高立永, 张弛, 等. 胃癌组织中基质金属蛋白酶2蛋白表达及微血管密度与患者临床病理特征的关系[J]. 肿瘤研究与临床, 2020, 32(6):400-404.

组别	例数	年龄/岁	性别		神经侵犯		肿瘤分期		血管侵袭
组别	例数	年龄/岁	男/例	女/例	有/例	无/例	Ⅰ期/例	Ⅱ期/例	有/例	无/例
复发组	37	64.4±7.3	20	17	9	28	16	21	9	28
未复发组	64	64.9±6.8	35	29	20	44	30	34	19	45
统计值		0.347	0.004		0.549		0.125		0.337
P值		0.731	0.951		0.459		0.724		0.562
组别	吸烟史		肺癌病理类型		体重质量/ （kg/m²）	肿瘤大小/cm	手术时间/ min		术中出血量/mL
组别	有/例	无/例	鳞癌/例	腺癌/例	体重质量/ （kg/m²）	肿瘤大小/cm	手术时间/ min		术中出血量/mL
复发组	23	14	15	22	23.08±2.29	3.3±1.2	177.24±24.56		113.78±24.65
未复发组	34	30	28	36	23.17±2.34	3.5±1.1	172.09±31.36		110.44±25.17
统计值	0.779		0.099		0.188	0.851	0.858		0.798
P值	0.376		0.753		0.852	0.397	0.393		0.427

组别	例数	年龄/岁	性别		神经侵犯		肿瘤分期		血管侵袭
组别	例数	年龄/岁	男/例	女/例	有/例	无/例	Ⅰ期/例	Ⅱ期/例	有/例	无/例
复发组	37	64.4±7.3	20	17	9	28	16	21	9	28
未复发组	64	64.9±6.8	35	29	20	44	30	34	19	45
统计值		0.347	0.004		0.549		0.125		0.337
P值		0.731	0.951		0.459		0.724		0.562
组别	吸烟史		肺癌病理类型		体重质量/ （kg/m²）	肿瘤大小/cm	手术时间/ min		术中出血量/mL
组别	有/例	无/例	鳞癌/例	腺癌/例	体重质量/ （kg/m²）	肿瘤大小/cm	手术时间/ min		术中出血量/mL
复发组	23	14	15	22	23.08±2.29	3.3±1.2	177.24±24.56		113.78±24.65
未复发组	34	30	28	36	23.17±2.34	3.5±1.1	172.09±31.36		110.44±25.17
统计值	0.779		0.099		0.188	0.851	0.858		0.798
P值	0.376		0.753		0.852	0.397	0.393		0.427

组别	例数	IL-8/（ng/L）	MMP-2/（ng/mL）
复发组	37	94.49±8.16	523.62±47.73
未复发组	64	83.48±7.51	451.41±42.04
t值		6.874	7.911
P值		<0.001	<0.001

组别	例数	IL-8/（ng/L）	MMP-2/（ng/mL）
复发组	37	94.49±8.16	523.62±47.73
未复发组	64	83.48±7.51	451.41±42.04
t值		6.874	7.911
P值		<0.001	<0.001

项目	β值	标准误	Wald值	OR值（95%CI）	P值
IL-8（≥87.52 ng/L）	3.334	0.784	24.983	24.50（18.94~37.23）	<0.001
MMP-2（≥477.86 ng/mL）	3.187	0.772	22.769	23.56（18.01~38.29）	<0.001